U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support ...

Parents of children with an incurable muscle-wasting condition have called on the Minister for Health to accelerate the ...

The parents of a nine-year-old boy battling a devastating muscle-wasting condition say new research could offer them more ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, ...

JAR of Hope helps support a team of researchers and doctors who are aiming to eliminate Duchenne muscular dystrophy – a fatal ...

Pathologic changes of the X-chromosome gene for dystrophin give rise to Duchenne muscular dystrophy (DMD), and dystrophin -- ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates ...

BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor ...